Objectives: Outbreaks of OXA-48-like carbapenemase producers are increasingly reported in many European countries and are often the result of difficulties in detection, especially for isolates with MICs of carbapenems that remain in the susceptibility range.
Introduction
OXA-48-like carbapenemases are increasingly identified in many European countries, such as France, Germany and the UK, through transfer of hospitalized patients from endemic areas, but also from likely autochthonous diffusion. 1, 2 The main reservoir of OXA-48-like producers is likely to be countries located on the southern to eastern borders of the Mediterranean Sea (Morocco to Turkey) and the Indian subcontinent.
1,2 Several outbreaks have been described that have often been the consequence of difficulties in detection, especially with isolates with low MICs of carbapenems that may remain in the susceptibility range. 1, 2 Several OXA-48 variants have been described: OXA-48, OXA-162, OXA-181, OXA-204 and OXA-232 hydrolyse carbapenems and hydrolyse broad-spectrum cephalosporins very weakly, while OXA-163 identified from Argentinean isolates lacks carbapenem-hydrolysing activity, but hydrolyses expandedspectrum cephalosporins. 2 The level of resistance to carbapenems provided by OXA-48-like-carbapenemase producers may vary significantly, making their detection difficult when based just on high levels of carbapenem resistance. Therefore, detection of OXA-48 producers is particularly challenging in a routine laboratory, especially in the course of managing an outbreak, when rapid identification and cohorting of patients is required. Several media have been proposed for the detection of carbapenemase producers. The ChromID ESBL medium has good sensitivity, its main disadvantage being its lack of detection of OXA-48-like producers that are susceptible to cefpodoxime in the absence of co-production of an extended-spectrum b-lactamase (ESBL). 3 The ChromAgar KPC medium has lower sensitivity due to lack of detection of bacteria with low MICs of carbapenems.
3 A Drigalski agar-based culture medium containing a carbapenem, cloxacillin and zinc sulphate (SUPERCARBA medium) has recently been described to identify accurately all carbapenemase-producing, including OXA-48-producing, Enterobacteriaceae. swabs or stool samples with comparable, if not superior, detection limits compared with culture has shown its usefulness due to a faster turnaround time of results (4 versus 48 h). 5, 6 Here, we describe the development of a qPCR assay combined with a fully automated extraction system for the detection of bla OXA-48-like genes from culture or from spiked stool samples.
Materials and methods

Bacterial strains and plasmids
Eleven well-characterized enterobacterial OXA-48-like producers (7 OXA-48, 2 OXA-181 and 2 OXA-163 producers), along with 14 non-OXA-48-like producers used as negative control strains, were used for direct detection in culture or for spiking experiments, in order to validate the novel detection assay (see Tables 1 and 2) . A recombinant plasmid, pOXA-48, consisting of a pCR-II-TOPO backbone (Invitrogen, Saint Aubin, France) carrying an 1 kb insert expressing the OXA-48 carbapenemase, was used for qPCR optimization. The concentration of the plasmid solution was 10 11 plasmid molecules/mL. MICs were determined using the Etest (bioMérieux, Marcy l'Étoile, France) and interpreted according to CLSI. 7 
Serial dilutions and spiking experiments
Bacterial suspensions of strains (see Table 2 ) with an optical density at 600 nm of 0.5 were serially diluted in PBS (bioMérieux); nine 10-fold dilutions were made. To quantify the viable bacteria in each dilution step, a blood agar plate (bioMérieux) was inoculated with 100 mL of a suspension and incubated overnight at 378C; the number of colonies that grew was counted the following day.
Spiked Escherichia coli cultures were prepared by adding 100 mL of each dilution in PBS was added to 900 mL of fresh overnight E. coli Ec1. 6 Spiked faecal samples were made by adding 100 mL of each dilution in PBS to 900 mL of a faecal suspension that was obtained by suspending 6 g of freshly pooled faeces from three healthy volunteers in 60 mL of distilled water, as previously described. 6 A faecal suspension without the addition of a bacterial strain was used as a negative control. Aliquots of 200 mL of spiked stool samples were subjected to DNA extraction. Each faecal suspension was plated onto the ChromID ESBL and SUPERCARBA media. Viable bacteria were counted after 24 h at 378C and growth on selective media was compared with qPCR results. All experiments were performed in triplicate.
DNA extraction from bacterial cultures and from stool samples
Fresh overnight bacterial cultures were used for DNA extraction with a QIAamp DNA Minikit (Qiagen, Les Ulis, France) according to the protocol suggested by the manufacturer. Extracted bacterial DNA was eluted from the columns in 200 mL of elution buffer and stored at 2208C.
Spiked E. coli Ec1 cultures and spiked stool samples were extracted with the EasyMag automated DNA extraction system (bioMérieux), which enables simultaneous DNA extractions from 24 samples in ,2 h.
OXA-48 qPCR assay
The qPCR Rotor-Gene 6000 amplification/detection system (Qiagen) was used for the amplification and detection of the bla OXA-48 amplicon (100 bp) by TaqMan technology. The forward PCR primer (OXA-48-For; 5 ′ -GTAGCAAAGGAATGGCAA-3 ′ ) and the reverse PCR primer (OXA-48-Rev; 5 ′ -CCTTGCTGCTTATTGTCA-3 ′ ) specific for the detection of bla OXA-48-like genes and the bla OXA-48 -specific probe [OXA-48-Probe;
[bracketed nucleotides with+signs are locked nucleic acid ('LNA') nucleotides] were designed in-house. The concentrations of the primers and probe used in this study that gave the best detection limits were 400 nM for bla OXA-48 primers and 200 nM for the bla OXA-48 probe. The Quantitect Virus Kit (Qiagen) was used as recommended by the manufacturer. One PCR experiment (including mix preparation and amplification) takes ,2 h. Simplexa TM from Focus Diagnostics (Eurobio, Courtaboeuf, France) was used as an internal control, for extraction and amplification. 6 
Results
The analytical sensitivity of the bla OXA-48 qPCR assay was determined after serially diluting plasmid pOXA-48. The amplification was linear over 10 log dilutions (r 2 ¼ 0.998 and slope ¼ 23.14), and the amplification efficiency was 1.10. The detection limit of the assay was reproducibly estimated at 10 plasmid molecules/PCR.
None of the OXA-48-negative bacterial pathogens was positive in the bla OXA-48 qPCR assay (Table 1) . Of the 14 isolates negative for the bla OXA-48 gene, 3 were imipenem susceptible and 11 were intermediate or resistant, by means of another carbapenemase gene. Of the 11 isolates positive for the bla OXA-48-like genes, 5 were susceptible to imipenem (MIC ,1 mg/L) and 6 were intermediate or resistant (MIC .4 mg/L). All were identified using this assay, with Ct values of 19 -20. Overall, there was 100% concordance between genotype of bacteria and the bla OXA-48 qPCR assay results (Table 1) , suggesting excellent specificities of the primers and probe. The assay identified OXA-48, OXA-181 and OXA-163 equally well.
The bla OXA-48 qPCR assay on extracted DNA from serially diluted OXA-48 producers into E. coli Ec1 and subsequent automated DNA extraction was linear over 9 log dilutions (r 2 ¼ 0.994 and slope ¼ 22.92), and the amplification efficiency was 1.09. The limit of the linear range of the qPCR was reproducibly 2×10 1 cfu. The qPCR allowed detection of 1 -5 cfu; however, the Ct values were out of the linear range of the qPCR.
The bla OXA-48 qPCR assay was capable of detecting 10-50 cfu/ 100 mg of faeces. Below 10 cfu (,1 equivalent cfu/PCR), results were not reproducible. The analytical sensitivity of the assay did not change upon the use of different bla OXA-48-like -positive strains with different carbapenem susceptibility patterns and different associated b-lactamases: Citrobacter freundii, Enterobacter cloacae, E. coli and Klebsiella pneumoniae bla OXA-48--positive strains ( Table 2) .
The qPCR results were compared with those obtained with two selective culture media: the chromogenic ChromID ESBL (bioMérieux) and SUPERCARBA. With serially diluted OXA-48 producers co-producing an ESBL or with OXA-163, which can hydrolyse expanded-spectrum cephalosporins, the lowest limit of detection ranged from 1×10 1 to 3×10 2 cfu/mL for ChromID ESBL (Table 2) . However, for isolates lacking an ESBL the detection limit was .10 5 cfu/mL (Table 2) . ChromID ESBL, which contains cefpodoxime as a selector and is routinely used for screening ESBL producers, 8 was capable of detecting carbapenemase-producing Enterobacteriaceae of the OXA-48 type, as long as a high level of resistance to cephalosporins was present due to an associated ESBL. 3 For SUPERCARBA medium, the lowest limit of detection of OXA-48 producers ranged between 1×10 1 and 3×10 1 cfu/mL ( Table 2 ). The Naas et al. qPCR detection of OXA-48 producers in stools SUPERCARBA screening medium, which may detect not only KPC b-lactamases and metallo-b-lactamases but also OXA-48 producers, 4 was capable of detecting all the carbapenemhydrolysing variants of OXA-48-like, even those with low MICs. OXA-163 was not detected on this medium, due to lack of carbapenem-hydrolysing activity.
Discussion
The prevention of spread of carbapenemase producers relies on early detection of carriers. Screened patients should be kept in strict isolation prior to obtaining the screening results, meaning that these screening techniques have to be sensitive, specific and rapid. Since the reservoir of carbapenemase producers remains the intestinal flora, stools and rectal swabs are adequate samples for performing this screening. ChromID ESBL is a reliable culture medium for screening most carbapenemase producers, except many OXA-48 producers, directly from faecal samples. 3 However, this medium is not capable of distinguishing between ESBL and carbapenemase producers. The SUPERCARBA medium represents a significant improvement compared with the available screening media to detect carbapenemase producers, particularly for the detection of OXA-48 producers that do not co-express an ESBL. In addition, this medium is useful for specifically selecting carbapenemase producers in stools that also contain a large amount of ESBL producers, the growth of which will be inhibited. 4 This property is particularly relevant, since high rates of ESBL carriage are now reported worldwide. 9 Alternative strategies, such as qPCR, have proven their usefulness for detecting KPC and for the management of epidemic situations. 8 Hindiyeh et al. 5 described the development and verification of a qPCR assay for detection of bla KPC genes directly in perianal swabs. Direct detection of bla KPC by PCR shortened the time to identification of patients colonized or infected with carbapenem-resistant organisms and was more sensitive than culture. Similarly, bla NDM-1 qPCR showed excellent sensitivity and specificity, with detection limits lower than those of the culture techniques, and with a significant gain in time to results (4 versus 48 h). 6 For OXA-48 qPCR, a similar time to results was observed: 2 h for automated extraction and ,2 h for qPCR. The OXA-48 qPCR thus yielded results in ,4 h, versus 2 -3 days using conventional methods. This qPCR assay is capable of detecting OXA-48, OXA-181 and OXA-163, an OXA-48 variant capable of hydrolysing third-generation cephalosporins but not carbapenems. 2 The newly described variants, OXA-162, OXA-204 and OXA-232, should also be detected using this qPCR assay, since the nucleotide changes between the variants are located outside the primer and probe binding sequences.
